NanOlogy Appoints David J. Arthur as Chief Executive Officer
NanOlogy, LLC, a company focused on advancing clinical-stage oncology, has announced the appointment of David J. Arthur as its new Chief Executive Officer. This significant move is expected to enhance NanOlogy's progression in the development of its Large Surface Area Microparticle (LSAM) drug portfolio, particularly in targeting Diffuse Intrinsic Pontine Glioma (DIPG), a challenging pediatric brain cancer that often leaves families with few treatment options.
David Arthur brings a wealth of experience to his role, boasting over 35 years within the pharmaceutical industry. His notable tenure includes leadership as the CEO of Salarius Pharmaceuticals, where he successfully transformed it into a clinical-stage oncology company and achieved a public listing on the NASDAQ. Before his recent role, David excelled in various executive positions at Eli Lilly and Boehringer Ingelheim for over 20 years, showcasing a robust background in product development and commercialization.
"We believe David is a fantastic addition to our team," stated H. Paul Dorman, founder and Chairman of NanOlogy. "His experience will be pivotal in accelerating our current drug development initiatives and exploring new business opportunities. NanOlogy has already initiated clinical trials across six solid tumors utilizing our LSAM investigational drugs. As we move forward, our goal includes finding strategic partners to advance these innovative therapies. Additionally, we are completing studies that will enable submission to the Food and Drug Administration for the treatment of a rare pediatric brainstem tumor, aiming to file an Investigational New Drug application soon. David's leadership will empower our organization to effectively navigate these critical developments and attract both strategic and financial partnerships necessary for our vision."
David Arthur expressed enthusiasm about his new role, stating, "I am truly impressed by the advances that NanOlogy has made in drug development. The potential for these intratumoral treatments, along with other unique delivery methods like inhalation, can significantly enhance treatment outcomes compared to traditional systemic cancer therapies. I aim to rapidly build on this progress and implement a strategic direction that benefits not just cancer patients but also delivers value for our shareholders."
About NanOlogy
NanOlogy, LLC specializes in developing innovative treatments for solid tumors specifically crafted for intratumoral application. This approach seeks to enhance efficacy while minimizing systemic side effects. Utilizing the advanced CritiTech Particle Engineering Solutions' Purcision technology, the company formulates Large Surface Area Microparticles (LSAMs) designed for direct local delivery, addressing systemic toxicity and bioavailability challenges prevalent in traditional therapeutic approaches. With clinical programs already advancing LSAM investigational drugs in various solid tumors such as pancreas, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers, the feasibility of the Purcision platform has been successfully demonstrated across several treatment categories. Furthermore, NanOlogy holds a robust intellectual property portfolio with over 100 issued patents globally, ensuring extensive protection over their investigational drugs and related technologies.
Media Contact
Marc Iacobucci
1-817-916-2247
SOURCE NanOlogy, LLC
Frequently Asked Questions
What is David J. Arthur's role at NanOlogy?
David J. Arthur is appointed as Chief Executive Officer to lead the clinical development of NanOlogy’s investigational drug portfolio.
What is NanOlogy focused on?
NanOlogy is focused on developing innovative oncology treatments, particularly for difficult-to-treat solid tumors.
What unique technology does NanOlogy utilize?
The company uses the CritiTech Particle Engineering Solutions' Purcision technology platform to create its LSAM drugs.
What are LSAM investigational drugs?
LSAM investigational drugs are designed for direct intratumoral delivery, aiming to improve efficacy while reducing systemic toxicity.
In which cancers is NanOlogy currently advancing its treatments?
NanOlogy is advancing treatments for multiple cancers, including pancreatic, lung, bladder, and pediatric brain tumors.
